InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by McGrath Yvonne, Vice-Présidente, Recherche et Développement et Directrice Scientifique. Director active across 2 companies, notably iTeos Therapeutics, Inc.. In total, 13 filings have been logged. Activity tracked since 17 May 2021. The latest transaction was filed on 7 March 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations13 total
15,300 shares0Common StockSEC:0000950170-25-037513:0
31,000 shares0Common StockSEC:0000950170-23-068903:0
10,000 shares@ US$4.2413.4% of flowCommon StockSEC:0001209191-22-015080:0
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-023000:0
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-023000
7,604 shares@ US$4.239.3% of flowCommon StockSEC:0000899243-21-021777:0
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-021779:0
7,604 shares@ US$4.239.3% of flowCommon StockSEC:0000899243-21-021777
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-021779
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-020733:0
7,927 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-020733
7,926 shares@ US$4.23100.0% of flowCommon StockSEC:0000899243-21-019921
7,926 shares@ US$4.239.7% of flowCommon StockSEC:0000899243-21-019921:0
13 of 13 declarations
About McGrath Yvonne
Yvonne McGrath is VP, Research and Development and Chief Scientific Officer at iTeos Therapeutics, Inc. In this role, she oversees the company's research and development initiatives, ensuring innovation and advancement of scientific projects. Her expertise is essential to support the organization's mission.
